60P to commence Phase II clinical trial among dengue fever patients 60 Degrees Pharmaceuticals.

It is designed to reduce the airway's capability to constrict, thereby lowering asthma attack frequency and severity.Â.. 60P to commence Phase II clinical trial among dengue fever patients 60 Degrees Pharmaceuticals, , a ongoing company centered on advancement of therapeutics for tropical diseases, and Singapore General Medical center announced today that the Hospital has received a grant from Singapore's National Medical Study Council to support a Phase II clinical trial among dengue fever patients. Dengue fever, a painful, debilitating and possibly deadly mosquito-borne viral disease, infects an estimated 400 million people world-wide each year, leading to 500,000 hospitalizations and creating a $12 billion annual burden.Yet another post hoc evaluation was performed for the primary outcome and loss of life from any cause by using data from the post-transition phase only. For analyses of outcomes, data from participants without final follow-up data were censored by the time of their last completed 4-month visit in both the intensive-therapy and standard-therapy organizations. Data on mortality for participants in the usa who were not really followed for the full follow-up period and who were not known to be deceased were censored by the most recent date they were known to be alive or January 1, 2008, based on the National Death Index.